Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL.

Literature DB >> 16885777

HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL.

Yumi Mitsuya¹, Mark A Winters, W Jeffrey Fessel, Soo-Yon Rhee, Sally Slome, Jason Flamm, Michael Horberg, Leo Hurley, Daniel Klein, Robert W Shafer.

Abstract

HIV-1 genotypic resistance test results were obtained on clinical samples from 116 patients with plasma HIV-1 RNA levels of less than 75 copies/mL. Genotype validity was confirmed in 49 of 50 patients with a previous or follow-up genotype. The belief that genotypic resistance testing is unreliable in samples with low-level viremia should be reassessed.

Entities: Disease Species

Mesh：

Substances：

Year: 2006 PMID： 16885777 PMCID： PMC2547468 DOI： 10.1097/01.qai.0000232609.99705.a2

Source DB: PubMed Journal: J Acquir Immune Defic Syndr ISSN： 1525-4135 Impact factor: 3.731

12 in total

1. Synonymous-non-synonymous mutation rates between sequences containing ambiguous nucleotides (Syn-SCAN).

Authors: Matthew J Gonzales; Jonathan M Dugan; Robert W Shafer
Journal: Bioinformatics Date: 2002-06 Impact factor: 6.937

2. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.

Authors: Gilbert Greub; Alessandro Cozzi-Lepri; Bruno Ledergerber; Schlomo Staszewski; Luc Perrin; Veronica Miller; Patrick Francioli; Hansjakob Furrer; Manuel Battegay; Pietro Vernazza; Enos Bernasconi; Huldrych F Günthard; Bernard Hirschel; Andrew N Phillips; Amalio Telenti
Journal: AIDS Date: 2002-09-27 Impact factor: 4.177

3. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia.

Authors: Nicola Mackie; Simon Dustan; Myra O McClure; Jonathan N Weber; John R Clarke
Journal: J Virol Methods Date: 2004-08 Impact factor: 2.014

4. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml.

Authors: Laura Waters; S Mandalia; David Asboe
Journal: AIDS Date: 2006-03-21 Impact factor: 4.177

5. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.

Authors: C de Mendoza; V Soriano; M Pérez-Olmeda; B Rodés; E Casas; J González-Lahoz
Journal: J Hum Virol Date: 1999 Nov-Dec

6. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals.

Authors: A N Phillips; V Miller; C Sabin; A Cozzi Lepri; S Klauke; M Bickel; H W Doerr; A Hill; S Staszewski
Journal: AIDS Date: 2001-12-07 Impact factor: 4.177

7. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.

Authors: R W Shafer; K Hertogs; A R Zolopa; A Warford; S Bloor; B J Betts; T C Merigan; R Harrigan; B A Larder
Journal: J Clin Microbiol Date: 2001-04 Impact factor: 5.948

8. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Authors: Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Donna M Jacobsen; Douglas D Richman
Journal: Clin Infect Dis Date: 2003-06-23 Impact factor: 9.079

HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL.

1. Synonymous-non-synonymous mutation rates between sequences containing ambiguous nucleotides (Syn-SCAN).

2. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.

3. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia.

4. Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml.

5. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.

6. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals.

7. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.

8. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

9. Virological rebound after suppression on highly active antiretroviral therapy.

10. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.

1. Clinical utility of genotypic resistance tests for HIV-1-infected patients with low-level virological failure.

2. HIV Drug Resistance Profiles and Clinical Outcomes in Patients with Viremia Maintained at Very Low Levels.

3. Adverse childhood experiences, mental health, substance use, and HIV-related outcomes among persons with HIV.

Review 4. HIV-1 antiretroviral resistance: scientific principles and clinical applications.